Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2022-12, Vol.29 (12), p.9813-9825
Main Authors: Woo, Stephanie M, Kimchy, Alexandra V, Sequeira, Lynette M, Dorris, Charles S, He, Aiwu R, Rangnekar, Amol S
Format: Article
Language:English
Subjects:
Analysis
Antimitotic agents
Antineoplastic agents
B7-H1 Antigen - metabolism
Carcinoma, Hepatocellular - surgery
Care and treatment
Complications and side effects
Graft Rejection - diagnosis
Graft Rejection - prevention & control
hepatocellular carcinoma
Hepatoma
Humans
immunosuppression
Immunotherapy
Immunotherapy - methods
Liver
liver cancer
Liver diseases
Liver Neoplasms - surgery
liver transplant
Liver Transplantation
Medical research
Medicine, Experimental
Mortality
Programmed Cell Death 1 Receptor - metabolism
Review
Transplantation
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol29120771